BMO Capital Starts Ra Pharma (RARX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Credit Suisse Starts Ra Pharma (RARX) at Outperform
November 21, 2016 6:57 AM ESTCredit Suisse initiates coverage on Ra Pharma (NASDAQ: RARX) with a Outperform rating and a price target of $19.00.
Analyst Kennen MacKay commented, "We view RA101495 as an attractive drug candidate for patients with paroxysmal nocturnal hemoglobinuria (PNH) with potential to capture >30% market... More
Jefferies Starts Ra Pharma (RARX) at Buy
November 21, 2016 6:51 AM ESTJefferies initiates coverage on Ra Pharma (NASDAQ: RARX) with a Buy rating and a price target of $25.00.
Analyst Eun Yang commented, "Utilizing its peptide chemistry platform, RARX focus on complement-mediated diseases. Given well-validated C5 target & encouraging Ph1 data, we view lead candidate... More
